Skip to content

Clinical study for collagen metabolism in patients with coronary heart disease and heart failure with Lixinshui prescription

Clinical study for collagen metabolism in patients with coronary heart disease and heart failure with Lixinshui prescription

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026368
Enrollment
Unknown
Registered
2019-10-04
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease and heart failure

Interventions

Sponsors

Yancheng Hospital of TCM affiliated to Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years, gender is not limited; 2) Meet the diagnostic criteria for coronary heart disease with heartfailure; 3) NYHA heart function level II-IV; 4) Comply with the diagnostic criteria of Chinese medicine "heart edema syndrome"; 5) Volunteer participation and signing informed consent.

Exclusion criteria

Exclusion criteria: 1) Acute exacerbation of chronic heart failure or acute heart failure; 2) Heart failure due to major organ failure such as liver and kidney; 3) The patient may undergo coronary artery bypass grafting or heart transplant surgery within the next 12 weeks; cardiac resynchronization therapy has been or may be performed; 4) Patients with severe primary diseases such as liver and kidney and endocrine and hematopoietic systems; 5) Have mental disorders, or malignant tumors; 6) Pregnant or pregnant women, lactating women; 7) Suspicious or clear allergies to the study drug; 8) Participate in other researchers in the past 2 months; 9) Factors that can aggravate mortality: such as severe ventricular arrhythmia, cardiogenic shock, complete atrioventricular block, obstructive cardiomyopathy, dilated cardiomyopathy, constrictive pericarditis, pericardial tamponade, hemodynamics Unstable unstable heart valve disease, pulmonary embolism, uncontrolled high blood pressure, and severe lung infections.

Design outcomes

Primary

MeasureTime frame
PICP;

Secondary

MeasureTime frame
PIIINP;ICTP;NT-proBNP;LVMI;MLHFQ;6 minutes walking distance;TCM syndrome points;NYHA;

Countries

China

Contacts

Public ContactXiaolong Song

Yancheng Hospital of TCM affiliated to Nanjing University of Chinese Medicine

edusongxiaolong@126.com+86 13912507419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026